Logo
x

Search

Subscribe Now

SMA

Novartis Lifts Partial Clinical Trial Hold on OAV-101 Clinical Program to Treat SMA

Novartis Lifts Partial Clinical Trial Hold on OAV-101 Clinical Program to Treat SMA

  • August 3, 2021
Novartis Presents New Data of Zolgensma in P-III Studies in Symptomatic Children with SMA at EAN2021

Novartis Presents New Data of Zolgensma in P-III Studies in Symptomatic Children with SMA at EAN2021

  • June 21, 2021
Roche and PTC Therapeutics Report Results of Risdiplam in FIREFISH Part 2 Study for Infants with Type 1 Spinal Muscular Atrophy

Roche and PTC Therapeutics Report Results of Risdiplam in FIREFISH Part 2 Study for Infants with Type 1 Spinal Muscular Atrophy

  • April 28, 2020
Novartis Reports Results of Zolgensma (onasemnogene abeparvovec-xioi) in P-III STR1VE Study for Spinal Muscular Atrophy (SMA) Type 1

Novartis Reports Results of Zolgensma (onasemnogene abeparvovec-xioi) in P-III STR1VE Study for Spinal Muscular Atrophy (SMA) Type...

  • April 17, 2019
Biogen's Spinraza (nusinersen) Receives NMPA (CFDA) Approval for Spinal Muscular Atrophy (SMA) Aged 6wks.

Biogen's Spinraza (nusinersen) Receives NMPA (CFDA) Approval for Spinal Muscular Atrophy (SMA) Aged 6wks.

  • March 1, 2019
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.